skip to main content
Idioma:
Refinado por: Nome da Publicação: Leukemia Research remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
87 A PHASE II STUDY OF THE EFFICACY AND SAFETY OF AN INTENSIFIED SCHEDULE OF AZACITIDINE IN HIGHER RISK MDS PATIENTS: A STUDY BY THE GFM
87 A PHASE II STUDY OF THE EFFICACY AND SAFETY OF AN INTENSIFIED SCHEDULE OF AZACITIDINE IN HIGHER RISK MDS PATIENTS: A STUDY BY THE GFM
Material Type:
Artigo 		Adicionar ao Meu Espaço

87 A PHASE II STUDY OF THE EFFICACY AND SAFETY OF AN INTENSIFIED SCHEDULE OF AZACITIDINE IN HIGHER RISK MDS PATIENTS: A STUDY BY THE GFM

Ades, L ; Guerci-Bresler, A ; Makhoul, P. Cony ; Legros, L ; Delaunay, J ; Recher, C ; Sebert, M ; Lejeune, J ; Chevret, S ; Fenaux, P

Leukemia research, 2015-04, Vol.39, p.S44-S44 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
2
142 MOLECULAR PROGNOSTIC FACTORS IN HIGHER RISK MDS RECEIVING FIRST LINE AZACYTIDINE (AZA)
142 MOLECULAR PROGNOSTIC FACTORS IN HIGHER RISK MDS RECEIVING FIRST LINE AZACYTIDINE (AZA)
Material Type:
Artigo 		Adicionar ao Meu Espaço

142 MOLECULAR PROGNOSTIC FACTORS IN HIGHER RISK MDS RECEIVING FIRST LINE AZACYTIDINE (AZA)

Ades, L ; Renneville, A ; Marceau, A ; Sebert, M ; Braun, T ; Nibourel, O ; Preudhomme, C ; Fenaux, P

Leukemia research, 2015-04, Vol.39, p.S72-S72 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
3
269 - Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). A Report of 9 Cases
269 - Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). A Report of 9 Cases
Material Type:
Artigo 		Adicionar ao Meu Espaço

269 - Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). A Report of 9 Cases

Attias, P. ; Renneville, A. ; Thomas, X. ; Bally, C. ; Hayette, S. ; Farhat, H. ; Eclache, V. ; Marceau, A. ; Cassinat, B. ; Feuillard, J. ; Terre, C. ; Delabesse, E. ; Park, S. ; Lejeune, S. ; Chevret, S. ; Ades, L. ; Preudhomme, C. ; Fenaux, P.

Leukemia research, 2017-04, Vol.55, p.S155-S155 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). A Report of 9 Cases
Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). A Report of 9 Cases
Material Type:
Artigo 		Adicionar ao Meu Espaço

Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). A Report of 9 Cases

Attias, P ; Renneville, A ; Thomas, X ; Bally, C ; Hayette, S ; Farhat, H ; Eclache, V ; Marceau, A ; Cassinat, B ; Feuillard, J ; Terre, C ; Delabesse, E ; Park, S ; Lejeune, S ; Chevret, S ; Ades, L ; Preudhomme, C ; Fenaux, P

Leukemia research, 2017-04, Vol.55, p.S155-S155 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
P-006 Prognostic value of TP53 gene mutations in higher-risk MDS treated with azacitidine (AZA)
P-006 Prognostic value of TP53 gene mutations in higher-risk MDS treated with azacitidine (AZA)
Material Type:
Artigo 		Adicionar ao Meu Espaço

P-006 Prognostic value of TP53 gene mutations in higher-risk MDS treated with azacitidine (AZA)

Bally, C ; Ades, L ; Renneville, A ; Mozziconacci, M.J ; Preudhomme, C ; DeThé, H ; Lehmann-Che, J ; Fenaux, P

Leukemia research, 2013-05, Vol.37, p.S25-S25 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
6
P-023 Incidence and prognostic value of TP53 mutations in IPSS low and INT 1 (lower risk) MDS with del 5q
P-023 Incidence and prognostic value of TP53 mutations in IPSS low and INT 1 (lower risk) MDS with del 5q
Material Type:
Artigo 		Adicionar ao Meu Espaço

P-023 Incidence and prognostic value of TP53 mutations in IPSS low and INT 1 (lower risk) MDS with del 5q

Bally, C ; Ades, L ; Renneville, A ; Preudhomme, C ; Raynaud, S ; Cluzeau, T ; Eclache, V ; Hunault-Berger, M ; Stamoullas, A ; Fontenay, M ; Mozziconacci, M.J ; De Thé, H ; Fenaux, P ; Lehmann-Che, J

Leukemia research, 2013-05, Vol.37, p.S32-S33 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
7
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
Material Type:
Artigo 		Adicionar ao Meu Espaço

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

Bally, Cecile ; Adès, Lionel ; Renneville, Aline ; Sebert, Marie ; Eclache, Virginie ; Preudhomme, Claude ; Mozziconacci, Marie-Joelle ; de The, Hugues ; Lehmann-Che, Jacqueline ; Fenaux, Pierre

Leukemia research, 2014-07, Vol.38 (7), p.751-755 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
P057 Abrogation of the DNA-damage response in AML versus MDS cell lines
P057 Abrogation of the DNA-damage response in AML versus MDS cell lines
Material Type:
Artigo 		Adicionar ao Meu Espaço

P057 Abrogation of the DNA-damage response in AML versus MDS cell lines

Boehrer, S ; Adès, L ; Braun, T ; Grosjean, J ; Fabre, C ; Fenaux, P ; Kroemer, G

Leukemia research, 2007, Vol.31, p.S71-S71 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
9
P068 Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome
P068 Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome
Material Type:
Artigo 		Adicionar ao Meu Espaço

P068 Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome

Boehrer, S ; Ades, L ; Gardin, C ; Hofmann, W.K ; Fenaux, P ; Kroemer, G

Leukemia research, 2009-05, Vol.33, p.S98-S99 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
10
P-283 Efficacy of salvage with decitabine (DAC) for high-risk (HR)-MDS and advanced CMML after azacitidine (AZA) treatment failure
P-283 Efficacy of salvage with decitabine (DAC) for high-risk (HR)-MDS and advanced CMML after azacitidine (AZA) treatment failure
Material Type:
Artigo 		Adicionar ao Meu Espaço

P-283 Efficacy of salvage with decitabine (DAC) for high-risk (HR)-MDS and advanced CMML after azacitidine (AZA) treatment failure

Braun, T ; Cherait, A ; Rigal, M ; Bréchignac, S ; Thépot, S ; Gardin, C ; Adès, L ; Fenaux, P

Leukemia research, 2013-05, Vol.37, p.S150-S150 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.